FGF21 and metabolic dysfunction-associated steatohepatitis: Moreover, FGF21 can also exert its anti-inflammatory effect by inhibiting the hepatocyte-Toll-like receptor 4-interleukin-17A pathway to prevent NASH from transitioning into hepatocellular carcinoma 191.